Article

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

02/12/2025

Excerpt from the Press Release: Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced plans for the next step in advancing…

Read More

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

02/11/2025

Excerpt from the Press Release: BOSTON, Feb. 6, 2025 /PRNewswire/ — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate.  The Safety…

Read More

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)

02/10/2025

Topline data from an interim analysis of the fourth cohort of its Phase 1b Multiple-Ascending Dose (MAD) clinical trial showed continued mechanistic dose response Exploratory results of imaging-based biomarkers continued to show reduction in height-adjusted total kidney volume (htTKV) growth rate Successful End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) with agreement…

Read More

Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial

02/07/2025

First Patient enrolled and treated at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital  Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies Excerpt from the Press Release: SAN DIEGO, Jan. 29, 2025 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer…

Read More

Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

02/05/2025

Excerpt from the Press Release: WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein. The interim data showed that a single intravenous dose of TX45 resulted in…

Read More

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

02/04/2025

January 30, 2025 Alterity Therapeutics – Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale – –  Key MRI Biomarker Shows Iron Stabilization in MSA Affected Brain Regions – –  ATH434 Demonstrated a Favorable Safety Profile – Excerpt…

Read More

BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancer

02/03/2025

BH-30643 is a macrocyclic, mutant selective OMNI-EGFR™ inhibitor with sub-nanomolar potency against classical and atypical EGFR mutations that is maintained even in the presence of T790M +/- C797S resistance mutations Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines…

Read More

Attovia Therapeutics Announces First Participant Dosed in First-in-Human Phase 1 Study of ATTO-1310, its Novel Half-life Extended Anti-IL-31 ATTOBODY for the Treatment of Chronic Pruritus

01/31/2025

ATTO-1310 offers a potential treatment for pruritic indications like CPUO where no approved treatments exist, and the potential for best-in-disease efficacy across pruritic conditions First drug candidate to enter the clinic that utilizes the company’s proprietary ATTOBODY platform, which offers best-in-class potency and unconstrained engineering potential Excerpt from the Press Release: FREMONT, Calif., Jan. 23,…

Read More

LAPIX Therapeutics Doses First Patient-In Phase 1b Clinical Trial of LPX-TI641 for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)

01/30/2025

Excerpt from the Press Release: CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) — LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company focused on developing novel, orally bioavailable immune system restoration therapies for autoimmune diseases based on agonism of TIM (T cell/transmembrane, immunoglobulin, and mucin receptor), today announced the dosing of first subject with its investigational…

Read More

Aro Biotherapeutics Doses First Patient in Phase 1b Trial of ABX1100 in Late-Onset Pompe Disease (LOPD)

01/29/2025

Trial aims to establish safety and provide proof of concept for GYS1 inhibition as promising new treatment strategy in patients with late-onset Pompe disease Dosing milestone extends momentum of ABX1100 development program, with data from normal healthy volunteers to be presented at WORLDSymposium™ in February Excerpt from the Press Release: PHILADELPHIA–(BUSINESS WIRE)–Aro Biotherapeutics, a clinical-stage…

Read More